Nivolumab-Induced Colitis in a Patient With Esophageal Adenocarcinoma: A Case Report

Nivolumab is an immune checkpoint inhibitor used in the treatment of several types of cancer. Among the adverse effects of this drug, immune-mediated colitis (IMC) has been described. However, in contrast to other checkpoint inhibitors, such as ipilimumab, drug-induced colitis due to nivolumab is no...

Descripción completa

Detalles Bibliográficos
Autores principales: Vlachos, Iakovos, Karamanolis, Georgios, Vezakis, Antonios, Dellaportas, Dionysios, Myoteri, Despoina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Pathology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442715/
https://www.ncbi.nlm.nih.gov/pubmed/37614260
http://dx.doi.org/10.7759/cureus.42315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442715/
https://www.ncbi.nlm.nih.gov/pubmed/37614260
http://dx.doi.org/10.7759/cureus.42315

Ejemplares similares